| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
At this moment, we do not have definite data about positive effects of Met inhibitors against transplanted ovarian clear cell carcinoma model. There are multiple reasons, but an important factor is that cell lines of ovarian clear cell carcinoma are slow-growing and difficult to obtain stable grafts in nude mice. We have analyzed tumors other than ovarian clear cell carcinomas, and Met amplification was confirmed in a subpopulation of endometrial cancers. On the other hand, breast cancers mostly had no amplification of the Met gene.
|
